Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Restructures Business Units After Six-Month Market Study

NEW YORK, July 12 (GenomeWeb News) - Sigma-Aldrich will restructure its two life science and research businesses in an attempt to tap into its customer base more efficiently, the company said today.


The organization will divide Sigma's existing scientific research and biotechnology businesses into three "customer-centric" units. Each unit will be overseen by a president, reporting to the company's president and chief operating officer.


The firm's SAFC business will not be affected, the company said.


Sigma said it took the steps, which take effect immediately, after a six-month market study. Sigma president and COO Jai Nagarkatti said the reorganization "should enable us to ... deliver 10 percent top and bottom line growth long-term."


The new business units will be:

  • Essentials, which represents 20 percent of the company's current sales, will offer "account management to largely economic buyers" in pharmaceutical, academic, and other commercial research organizations. Gilles Cottier, vice president of sales at Sigma, will head the unit.
  • Specialties, which represents 35 percent of the company's current sales, will sell Sigma's products through its web site and catalogs to lab scientists. David Julien, most recently president of Sigma's biotechnology business, will run this business.
  • Biotech, which represents 20 percent of the company's current sales, will sell certain research tools for life scientists. This group will be headed by Shaf Yousaf, most recently vice president of corporate R&D and biotech marketing.

SAFC, represents 25 percent of Sigma's sales after the recent acquisition of JRH Biosciences, will sell fine chemical products and services. This unit "stands separate" from the other three. SAFC will continue to be led by Frank Wicks, who has served as the unit's president since January 2003.

Sigma said it plans to continue reporting sales results for the three existing scientific research, biotechnology, and SAFC units through 2005 and begin reporting under the new four-unit structure in 2006.

Additional details were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.